Huperzine a provides neuroprotection against several cell death inducers using in vitro model systems of motor neuron cell death

Neurotoxicity Research

Volumn 13, Issue 1, 2008, Pages 49-61

  Hemendinger, Richelle A ^a   Armstrong III, Edward J ^a   Persinski, Rafal ^a   Todd, Julianne ^a   Mougeot, Jean Luc ^a   Volvovitz, Franklin ^b   Rosenfeld, Jeffrey ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

^b Biomedisyn Corporation   (United States)

Author keywords

ALS; Apoptosis; Caspase; Huperzine A; Motor neuron; Neuroprotection; Organ culture

Indexed keywords

3 HYDROXYASPARTIC ACID; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CHOLINE ACETYLTRANSFERASE; HUPERZINE A; HYDROGEN PEROXIDE; STAUROSPORINE; THAPSIGARGIN; 3-HYDROXYASPARTIC ACID; ASPARTIC ACID; DRUG DERIVATIVE; ENZYME INHIBITOR; IONOPHORE; NEUROPROTECTIVE AGENT; OXIDIZING AGENT; SESQUITERPENE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL DEATH; CELL FUSION; CELL LINE; CELL METABOLISM; CELL NUCLEUS; CELL SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DEGENERATIVE DISEASE; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOTONEURON; MOTOR NEURON DISEASE; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD NERVE CELL; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CYTOLOGY; DRUG EFFECT; DRUG INTERACTION; ORGAN CULTURE TECHNIQUE; PATHOLOGY; SPINAL CORD; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; APOPTOSIS; ASPARTIC ACID; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; CELL LINE; DRUG INTERACTIONS; ENZYME INHIBITORS; HYDROGEN PEROXIDE; IONOPHORES; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; ORGAN CULTURE TECHNIQUES; OXIDANTS; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; SPINAL CORD; STAUROSPORINE; THAPSIGARGIN;

EID: 44649119542     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033367     Document Type: Article

References (39)

1. Boillee S, VC Vande and DW Cleveland (2006) ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron 52, 39-59.
2. Bordet T, R Pruss and CE Henderson (2006) Screening for ALS drugs, In: Amyotrophic Lateral Sclerosis (Mitsumoto S, S Przedborski and PH Gordon, Eds.) (Taylor & Francis Group:NEw York, NY, USA), pp 551-582.
3. Clement AM, MD Nguyen, EA Roberts, ML Garcia, S Boillee, M Rule, AP Mahon, W Doucette, D Siwek, RJ Ferrante, RH Brown Jr, JP Julien, LS Goldstein and DW Cleveland (2003) Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302, 113-117.
4. Cluskey S and DB Ramsden (2001) Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol. Pathol. 54, 386-392.
5. Dvir H, HL Jiang, DM Wong, M Harel, M Chetrit, XC He, GY Jin, GL Yu, XC Tang, I Silman, DL Bai and JL Sussman (2002) X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: Structural evidence for an active site rearrangement. Biochemistry 41, 10810-10818.
6. Gao X anc XC Tang (2006) Huperzine A attenuates mitochondrial dysfunction in beta-amyloid-treated PC 12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism. J. Neurosci. Res. 83, 1048-1057.
7. Gordon RK, S V Nigam, JA Weitz, JR Dave, BP Doctor and HS Ved (2001) The NMDA receptor ion channel: A site for bind- ing of Huperzine A. J. Appl. Toxicol. 21 Suppl. 1, S47-S51.
8. Guegan C and S Przedborski (2003) Programmed cell death in amyotrophic lateral sclerosis. J. Clin. Invest. 111, 153-161.
9. Hemendinger RA and SE Bloom (1998) Differential induction of apoptosis and cell cycle inhibition by the mitochondrial poisons Rhodamine 123 and carbonyl cyanide m-chlorophenyl in B lymphoma vs T lyphoma cells. In Vitro Mol. Toxicol. 11, 229-242.
10. Hemendinger R, J Wang, S Malik, R Persinski, J Copeland, D Emerich, P Gores, C Halberstadt and J Rosenfeld (2005) Sertoli cells improve survival of motor neurons in SOD1 transgenic mice, a model of amyotrophic lateral sclerosis. Exp. Neurol. 196, 235-243.
11. Ince PG, J Tomkins, JY Slade, NM Thatcher and PJ Shaw (1998) Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: Molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. J. Neuropathol. Exp. Neurol. 57, 895-904.
12. Jorda EG, E Verdaguer, A Jiménez, AM Canudas, V Rimbau P Camps, D Muñoz-Torrero, A Camins and M Pallàs (2004) (±)-huprine Y, (-)-huperzine A and tacrine do not show neu- roprotective properties in an apoptotic model of neuronal cytoskeletal alteration. J. Alzheimer's Dis. 6, 577-583.
13. Jorda EG, E Verdaguer, A Jiménez, SG de Arriba, C Allgaier, M Pallàs and A Camins (2005) Evaluation of the neuronal apoptotic pathways involved in cytoskeletal disruptioninduced apoptosis. Biochem. Pharmacol. 70, 470-480.
14. Kaufmann P (2006) ALS pharmacolotherapy: Riluzole and clinical trials, In: Amyotrophic Lateral Sclerosis (Mitsumoto S, S Przedborski and PH Gordon, Eds.) (Taylor & Francis Group:NEw York, NY, USA), pp 665-689.
15. Klein SM, S Behrstock, J McHugh, K Hoffmann, K Wallace, M Suzuki, P Aebischer and CN Svendsen (2005) GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther. 16, 509-521.
16. Lacomblez L, G Bensimon, PN Leigh, P Guillet and V Meininger (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347, 1425-1431.
17. Lee MS, YT Kwan, M Li, J Peng, RM Friedlander and LH Tsai (2000) Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364.
18. Ma YX, Y Zhu, Q Gu and L He (1998) Double-blind trial of huperzine-A (HUP) on cognitive deterioration in 314 cases of benign senescent forgetfulness, vascular dementia and Alzheimer's disease. Ann. NYAcad. Sci. 854, 506-507.
19. Martin D, MA Thompson and JV Nadler (1993) The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 250, 473-476.
20. McKinney M, JH Miller, F Yamada, W Tuckmantel and AP Kozikowski (1991) Potencies and stereoselectivities of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase. Eur. J. Pharmacol. 203, 303-305.
21. Nguyen MD, M Boudreau, J Kriz, S Couillard-Després, DR Kaplan and J-P Julien (2003) Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J. Neurosci. 23, 2131-2140.
22. Pollak A and G Ciancio (1990) Cell cycle phase-specific analysis of cell viability using Hoechst 33342 and propidium iodide after ethanol preservation, In: Methods in Cell Biology: Flow Cytometry (Darzynkiewicz Z and H Crissman, Eds.) (Academic Press:SAn Diego, CA, USA), pp 19-24.
23. Rametti A, F Esclaire, C Yardin and F Terro (2004) Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J. Biol. Chem. 279, 54518-54528.
24. 1 to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am. J. Pathol. 162, 823-835.
25. Rothstein JD, L Jin, M Dykes-Hoberg and RW Kuncl (1993) Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA 90, 6591-6595.
26. Shaw PJ (2005) Molecular and cellular pathways of neurodegeneration in motor neurone disease. J. Neurol. Neurosurg. Psychiatry 76, 1046-1057.
27. Shelton SB, P Krishnamurthy and GVW Johnson (2004) Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain corti- cal cells. J. Neurosci. Res. 76, 110-120.
28. Simpson EP, AA Yen and SH Appel (2003) Oxidative stress, a common denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr. Opin. Rheumatol. 15, 730-736.
29. Tang LL, R Wang and XC Tang (2005) Huperzine A protects SHSY5Y neuroblastoma cells against oxidative stress damage via nerve growth factor production. Eur. J. Pharmacol. 519, 9-15.
30. Tang XC, SP De, K Sugaya and E Giacobini (1989) Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J. Neurosci. Res. 24, 276-285.
31. Wang C, XC Zhang, H Ma, J Liu, F Fu and K Liu (2007) Prolonged effects of poly(lactic-cp-glycolic acid) microspherecontaining huperzine A on mouse memory dysfunction induced by scopolamine. Basic Clin. Pharmacol. Toxicol. 100, 190-195.
32. Wang R and XC Tang (2005) Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease. Neurosignals 14, 71-82.
33. Wang R, HY Zhang and XC Tang (2001) Huperzine A attenuates cognitive dysfunction and neuronal degeneration caused by beta-amyloid protein-(1-40) in rat. Eur. J. Pharmacol. 421, 149-156.
34. Xiao XQ, HY Zhang and XC Tang (2002) Huperzine A attenuates amyloid beta-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J. Neurosci. Res. 67, 30-36.
35. Zhang HY and XC Tang (2003) Huperzine A attenuates the neurotoxic effect of staurosporine in primary rat cortical neurons. Neurosci. Lett. 340, 91-94.
36. Zhang HY, YQ Liang, XC Tang, XC He and DL Bai (2002) Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid (25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice. Neurosci. Lett. 317, 143-146.
37. Zhao YJ, P Yue, T Tao and QH Chen (2007) Drug brain distribution flowing intranasal administration of Huperzine A in situ gel in rats. Acta Pharmacol. Sin. 28, 273-278.
38. Zhou J and XC Tang (2002) Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBSLett. 526, 21-25.
39. Zhou J, Y Fu and XC Tang (2001) Huperzine A protects ratpheochromocytoma cells against oxygen-glucose deprivation. Neuroreport 12, 2073-2077.